TrialBlood cancer journal2024

Bispecific CAR-T cells targeting CD19/20 in patients with relapsed or refractory B cell non-Hodgkin lymphoma: a phase I/II trial.

Lixin Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.